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ABSTRACT OF THESIS:

AGGRESSIVE DIURESIS AND SEVERITY-ADJUSTED LENGTH OF HOSPITAL
STAY IN ACUTE CONGESTIVE HEART FAILURE PATIENTS

To see if aggressive diuresis in first twenty four hours is associated with a
comparable number of total days in the hospital as compared to non-aggressive diuresis.
In this retrospective cohort study, we compared the length of hospital stay of consecutive
patients admitted in one year based on their diuresis during the first twenty-four hours of
hospitalization: aggressive diuresis (group 1) i.e. >2400mL versus non-aggressive
diuresis (group 2) i.e. ≤ 2400mL urine output. Patients were excluded if in cardiogenic
shock, had creatinine level above 3 mg/dL on admission, or on dialysis. A total of 194
patients were enrolled (29 in group 1 and 165 in group 2 respectively). The Kaplan-Meier
estimate of the median cumulative proportion of patients still hospitalized for the group 1
was 4 days and in group 2 was 5 days (log-rank test; P=0.67). In univariate analysis, Cox
PH regression showed unadjusted hazard rate of discharge from hospital was slightly
higher in group 1 than group 2 but was statistically non-significant (HR=1.08; P=0.70).
In multivariate Cox model analysis, creatinine at the time of admission when greater than
1.6mg/dL (P=0.75), LVEF (P= 0.14), total twenty-four hours dose of intravenous
Furosemide given (P=0.98) and interaction between Furosemide dose and Creatinine
level (P=0.79) were not significant predictor of hospital discharge. Adjusted hazard rate
for discharge from hospital was 12% higher in group 1 than group 2 but still statistically
non-significant (HR=1.12; P=0.60). Since the length of hospital stay is similar between
two groups, we suggest the goal of diuresis to be less than 2400mL in first twenty four
hours to prevent excessive dehydration.
Keywords: Aggressive Diuresis, Furosemide, length of hospital stay, Chronic Kidney
Disease
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1.1 BACKGROUND:
Heart failure is a clinical syndrome associated with reduced effective blood
pumping capacity of the heart. Congestive Heart Failure(CHF) is a global pandemic
affecting at least 26 million people worldwide and 6.5 million people in the US with age
≥ 20 years.1 Increase in incidence and prevalence of CHF is not due to the failure in
treatment but an increased survival in the aging population who suffer from Acute
Coronary Syndrome and related diseases of the heart. Heart failure is the most common
diagnosis related reason for hospitalization in ≥ 65-year-old patients. The total direct cost
of the CHF patients has been estimated to be around $ 20 to $ 40 billion annually with the
mean estimated cost of each hospitalization of $14,631. Economic burden of CHF is
further compounded by about 25% readmission rate within 30 days.2 National average
length of hospital stay is around 6 to 8 days.3,4 Medicare reimbursement for CHF patient
is linked to the length of hospital stay and quality measures.4 There are situations during
uncomplicated hospital admission, where expenses borne by the hospital exceed the
reimbursement from insurance companies incurring undesirable financial penalties.
There is an inherent desire to shorten the length of hospital stay without increasing the
morbidity, mortality, and hospital re-admission rate.
Acute CHF is associated with on average up to 15 to 20 liters of extra fluid in the
body. There are multidimensional approaches in the treatment of CHF depending on the
etiology, type, and severity of CHF, but diuretics have been the time-tested cornerstone
of every treatment. Loop diuretics are the effective first line diuretic therapy.5 Relieving
congestion is the primary goal, but it is not always free from adverse effects of
hypotension, worsening of renal function, electrolytes abnormality, and arrhythmias.
1

There are no clinical trials that define the ideal diuretic dose, thus, dosing is largely based
on iterative increases with observation of patients for urine output, subjective assessment
of patient fluid overload status, ejection fraction, home dose of diuretics, blood pressure
at presentation, concurrent use of other medications, comorbidities, and renal function.
Practically speaking, after hospital admission with acute congestive heart failure, the
patient is empirically given the first dose of diuretic in the emergency room. As the
patient is reassessed and given a subsequent dose of a loop diuretic, the relief of
symptoms and ultimately the length of hospital stay depend partly on weight change or
indirectly urine output. A common observation is that a high dose of diuretic does not
necessarily translate into greater urine output in many situations, as numerous variables
confound this relationship i.e. tolerance to diuretics, decrease GI absorption,
hyperchloremia, and the severity of CHF and renal dysfunction at baseline or during the
hospital stay. The goal of therapy is to maximize the urine output, but too much diuresis
in a short time can lead to adverse effects. All treatments are directed towards starting
certain adequate dose loop diuretic, but there is no magic number. The dose of diuretic
given is merely one of the factors that can affect subjective relief of symptoms and length
of hospital stay, but final urine output achieved by a diuretic dose has more intuitive and
deterministic role practically.6 It is the eventual objective outcome depicting the effect of
a diuretic. Thus, adequate diuresis achieved initially irrespective of starting dose of
diuretic used can be assumed to have a direct role in relieving fluid overload symptoms.
The total dose of diuretic given in first twenty-four hours which is highly variable likely
helps to choose the subsequent tolerable dose, but it is only one of the factors determining
the amount of urine if comorbidities or adverse effect of diuresis do not complicate the
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course of the hospital. The DOSE trial addressed the primary question if symptomatic
improvement, worsening of renal function is related to low vs. high dose of loop diuretic
given as continuous vs. bolus dose protocols.7 This study did not find any difference in
primary endpoint as well as its prespecified secondary endpoint of any difference in the
length of hospital stay between four groups. But the study was not powered to detect the
difference in the length of hospital stay, more so ever there was no comparison of urine
output between the groups. However, two observational studies, first by Howard and
Dunn and later by Li and Hong found that aggressive diuretic therapy to achieve greater
than 100mL/hour (≥ 2400mL/ 24) of urine leads to a shorter length of hospital stay.3,8
Therefore, there are conflicting results between the dose of diuretic, subsequently urine
output and length of hospital stay. Numerous studies have addressed the relationship
between the dose of diuretic and length of hospital stay, but here we rather propose to
examine the more direct relationship between the amount of diuresis in first twenty-four
hours irrespective of dose of a loop diuretic and disease severity-adjusted length of
hospital stay.

1.2 OBJECTIVES:
PRIMARY OBJECTIVE
The dose of diuretic is directly related to the urine output if there are no untoward
effects and other disease severity associated predictors are accounted for. The higher the
urine output, the earlier the relief of symptoms and the shorter the length of hospital stay.
Since fluid overload is the primary pathological mechanism in acute congestive heart
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failure patients, theoretically, diuresis driven by urine output itself achievable by any
dose of diuretic would be better able to determine the decongestion and length of hospital
stay. Patients will be divided into aggressive diuretic therapy group and non-aggressive
diuresis group by the criterion used by Howard and Dunn.3 Expectantly it will be of
interest to see if higher urine output leads to a shorter hospital stay.
Hypothesis:
Patients who had aggressive diuresis in first twenty-four hours (urine output ≥
2400mL/24 hour) will have a different a length of hospital stay than patients who had
less-aggressive diuresis. (urine output < 2400mL/24hour) irrespective of the dose of loop
diuretics.
DESCRIPTIVE OBJECTIVE:
1 Study the association of dose of diuretics in first twenty-four-hour urine output using
univariate and multivariate analysis, defining the predictors of association.
2 Study the risk of developing adverse effects as arrhythmia, worsening of renal function,
electrolyte abnormality, and death in aggressive and non-aggressive diuretic therapy
group.
STUDY DESIGN AND METHODS:
2.1 STUDY DESIGN AND POPULATION:
To examine the association between the amount of urine output in first twentyfour hours in acute CHF patients and the total length of hospital stay we propose to
conduct a retrospective cohort study utilizing data from Mercy Hospital of South Buffalo,
4

affiliated with the State University of Buffalo. This hospital has a capacity of 450 beds
and serves a population of approximately1,500,000. Acute medical care of CHF is
provided predominantly by residents, fellows, internists, and cardiologists. Patients
admitted to the acute general medical wards and Cardiac Care Units either as a first
diagnosis or an exacerbation of pre-existing HF between 2014 and 2015 will be
prospectively identified by using International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] diagnosis code. Detailed data will be recorded
retrospectively from the hospital records of each index hospital admission. The study will
not include any vulnerable population.
2.2 INCLUSION CRITERIA:
Patients included will be 18- 80 years old who presented with new onset or
chronic CHF diagnosed by elevated filling pressures, indicated by one symptom and one
physical sign regardless of ejection fraction.
•

Symptoms: Dyspnea at rest, in the supine position, or immediately upon
routine activity within one room; abdominal discomfort, severe anorexia,
or nausea without apparent cause other than hepatosplanchnic congestion.

•

Signs: Jugular venous pressure elevation >10 cm above the right atrium;
hepatomegaly, ascites, or edema in the absence of other apparent causes;
rales greater than 1/3 lung fields and/ or pleural effusion.

•

Imaging documentation: of congestive heart failure including pulmonary
vascular congestion in chest x-ray will supplement the signs and
symptoms.
5

2.3 EXCLUSION CRITERIA:
•

Patients will be excluded if creatinine level greater than 3 mg/dl on admission or
if the patient is on dialysis.

•

Patient will also be excluded if in cardiogenic shock defined as systolic blood
pressure below 90 mm Hg and requiring the use of inotropic medication or
mechanical support.

•

Patient will be excluded if they had any acute concurrent medical illness as Acute
Coronary Syndrome, COPD or Asthma Exacerbation.

2.4 OUTCOME ASSESSMENT:
It is the time to event analysis. The event of interest (endpoint) will be discharge
from the hospital. Time origin is the date of admission to the hospital. Survival time is the
length of hospital stay, i.e. time interval in days measured from the day of admission to
final discharge from the hospital. We anticipate we will be observing the event in all the
patients admitted to the hospital within 30 days of admission (patient follow up time). If
the event is not recorded in medical records as day of discharge from the hospital, then
observation will be considered censored at last day of available record in the system.
Patient will also be censored if patient died of any cause during hospitalization or if the
patient is still in the hospital at the end of the calendar study time of study December 31,
2015.
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2.5 EXPOSURE ASSESSMENT:
Exposure of interest is the after hospitalization first twenty-four hours maximum
urine output (in milliliters). It will involve abstraction of the data from medical records
within first twenty-four hours when the patient was either in the Emergency Room,
medical floor or Cardiac Care Unit. Urine output initially will be measured as a
continuous variable but later it will be dichotomized into two categories as aggressive
diuretic therapy group (with urine output greater than 2400mL/1st 24 hours) and nonaggressive diuretic therapy group (with urine output less than or equal to 2400mL/1st 24
hours).
2.6 COVARIATE ASSESSMENT:
Data for covariates will be abstracted from the medical record (see table Variable
Description table 1). Apart from demographic characteristics, data will be obtained about
the type of CHF i.e. systolic or diastolic type of CHF, Ejection Fraction (EF) of the left
ventricle, systolic blood pressure and serum creatinine at the time of admission.
Creatinine will be further dichotomized into two categories to define stages of Chronic
Kidney Disease (CKD) i-e less than or equal to Stage III CKD (lesser than 1.6mg/dL) and
equal or greater than Stage IV CKD (higher than 1.6mg/dL). The total maximum dose of
loop diuretics exclusively Furosemide given either as an intravenous bolus or continuous
intravenous infusion in first twenty-four hours will be noted. Information regarding any
adverse events occurred during hospitalization will be recorded which will include death,
arrhythmia, worsening of renal function and hypotension.
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Table 1 Variable Description

Variable
Name

Description of Variable

ID

Patient ID

AGE

Age in years at the time of admission.

Continuous

SEX

Gender of the patient
0=Female
1=Male

Dichotomous

RACE

Race of the patient
0= white
1=non-white

Dichotomous

EVENT

Event of interest is the discharge from the
hospital.
1= Discharge from the hospital.
0= Censored. No record of discharge from the
hospital or patient died during hospitalization,
or patient still in the hospital when study
calendar time or patient follow up time ended.

Dichotomous

TIME

Time measured in number of days from the
time of admission (origin) to the hospital to
the day of discharge (event) from the hospital.

Continuous

FUROSEMI

The generic name of a type of a loop diuretic
used. It denotes total 24-hour dose of
Furosemide in mg given either IV continuous
or IV Bolus in 1st 24 hours.

Continuous

URINE

Total first twenty-four-hour urine output
measured in mL after admission to the
hospital.

Continuous

URINECAT

Total 1st 24-hour urine output measured in
mL after admission to the hospital divided
into
0=Non-aggressive Diuresis (less than
or equal 2400mL urine output in 1st
24-hour)

Dichotomous

DE
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Type of
Variable

1=Aggressive Diuresis (more than
2400mL urine output in 1st 24-hour).
CR

Serum creatinine measured in mg/dL on the
day of admission to the hospital.

Continuous

CRCAT

Serum Creatinine dichotomized into two
categories
0= less than or equal 1.6mg/dL
(equivalent to stage 3 or less kidney
disease)
1= greater than 1.6 mg/dL (equivalent
to stage 4 or greater kidney disease

Dichotomous

EF

Ejection fraction of the left ventricle of heart
on echocardiography (%).

Continuous

BP

Systolic blood pressure at the time of
admission to hospital in mmHg.

Continuous

CHF

Type Congestive Heart Failure(CHF).
0= Systolic CHF
1=Diastolic CHF

Dichotomous

WORSEKID

Worsening of kidney function during
hospitalization. It is defined as 0.3 mg/dL
increase in the creatinine or 50% increase in
the creatinine from baseline (admission day)
in 1st 24 hours.
0=No worsening
1=Yes worsening
Defined as atrial or ventricular
tachyarrhythmia lasting greater than one
minute.
0=No
1=Yes

Dichotomous

All-cause death from any cause.

Dichotomous

NEY

ARRHYTH
MIA

DEATH

Dichotomous

0=No
1=Yes

HYPOTENS
ION

Low blood pressure (less than 90mmHg)
after 1st 24 hours.
0=No
1=Yes
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Dichotomous

2.7 SAMPLE SIZE AND POWER:
Study size and power estimate will be based on the median number of days of
hospital stay using the Log-Rank test method. Previously studies have noted median
hospital stay of 7 days.4 We expect this median hospital stay in the hospital for the nonaggressive cohort (to be reference group). We anticipate clinically crucial minimum
effect size of 3 three-day difference. The Type I error level is chosen as 0.05 for the twosided hypothesis. The hospital has about 450 admissions with primary diagnosis of CHF
each year. If we exclude 200 patients as a liberal guess not meeting inclusion criterion,
then, we still have 100 patients in each arm which will give us the power of more than
0.90.
The details of the Log-Rank test method were applied using SAS (see Appendix).
Total study time will be one calendar year i-e January 1, 2014, to December 31, 2014.
There will be no accrual period; patient follow up will be from the day of admission to
the hospital to final discharge up to 30 days. It is anticipated that event of interest
(discharge) will be observed in all the patients and there will be no correction for loss to
follow-up, treatment discontinuation, and other forms of censoring.
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SAS PROGRAM CODING AND OUTPUT:
PROC POWER;
TWOSAMPLESURVIVAL TEST=LOGRANK
GROUPMEDSURVTIMES = (4 7)
ACCRUALTIME = 0
FOLLOWUPTIME = 30
GROUPNS = 100 | 100
POWER = .;
RUN;

Power analysis of Length of Hospital Stay and Aggressive vs non-Aggressive Diuresis:
The POWER Procedure
Log-Rank Test for Two Survival Curves

Fixed Scenario Elements
Lakatos normal approximation

Method
Form of Survival Curve 1

Exponential

Form of Survival Curve 2

Exponential
0

Accrual Time

30

Follow-up Time
Group 1 Median Survival Time

4

Group 2 Median Survival Time

7

Group 1 Sample Size

100

Group 2 Sample Size

100
2

Number of Sides

12

Number of Time Sub-Intervals
Group 1 Loss Exponential Hazard

0

Group 2 Loss Exponential Hazard

0
0.05

Alpha

Computed
Power
Power
0.970

11

STUDY TIME:
Stage 1: Review of medical Records 8 months.
Stage 2: Data collection and data analysis 1-2 months.
Stage 3: Presentation and publication 3-4 month.

2.8 DATA MANAGEMENT:
This is a retrospective review of medical records. Patient confidentiality will be
maintained, and data will be de-identified. There will be no breach of subjects’ privacy.
The retrospective review does not involve patient’s contact or consent

since research

does not involve more than minimal risk to subjects. Each patient will be assigned a
unique identifier that will have no meaning to the study database (it will not incorporate
subject name, medical record number). The patient identifier will be kept separately from
main data. Principle investigator himself will transcribe data into the database. Only
principle investigator and research mentors will have access to paper data entry forms
and electronic database. Study database will be encrypted with a password, backed up
regularly and will be stored offsite as well.
At the end of original study data, data dictionary and final data will be archived
for three years for the investigator to respond to queries about the integrity of data or
analysis. Any health care professional may request data provided University IRB
approves it, and it complies with HIPAA. Principle investigator or research mentor may
be contacted for this purpose. Patient data will be de-identified before that.
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Missing values, outliers, and other data problems will be identified by using
queries and will be cross-checked with medical records.
Crossfield validation will also be done for values within allowed ranges but
inconsistent with one another.
We will maintain the audit log for all data changes. Editing procedure will be
repeated with few errors identified, and then data will be finalized and or frozen so that
no further changes can be made.
MISSING DATA:
Although every effort will be made to avoid missing data, patients with missing
data will be compared to patients with complete data to describe potential bias due to
differential loss of data. We will also explore methods for imputing missing data using
maximum likelihood methods and will apply these in the presence of incomplete and
missing data to reduce bias and increase the precision.
2.9 STATISTICAL ANALYSIS PLAN:
We propose to evaluate the association between aggressiveness of diuresis and
length of hospital stay.
Univariate Analysis:
We will present the number and percent of subjects included in the study
population before exclusion. Univariate analysis will be done to look for outliers and
ranges. We will do normality test by using Shapiro Wilk test statistically and Q-Q plot
13

visually. Normally distributed data will be presented as mean and standard deviation and
the non-normal data as median and interquartile(IQ) range. We will present categorical
data as frequencies and percentages of the total.
Bivariate Analysis:
We will cross-tabulate covariates with exposure and outcomes for sensitivity
analysis to address any potential bias and confounding. Cross with exposure (aggressive
vs. non-aggressive group) will be evaluated with the Chi-square test to determine whether
the observed distribution fits the expected distribution when the cell size is sufficient.
When the cell size is not enough Fisher’s exact test will be used. P values reflecting the
differences in distribution will be presented for all the covariates. For continuous
covariates, independent samples t-test will be used to compare the mean between two
aggressive and non-aggressive groups for normally distributed data whereas MannWhitney U test will be used for non-normal data. Confidence intervals for the difference
between two medians will be calculated using Hodges-Lehmann estimates.
Non-parametric Kaplan Meier method will be used to compare the proportion of
patients discharged from the hospital (or 1- accumulated proportion of patient still in
hospital) between aggressive versus non-aggressive diuresis group. Survival curves will
be compared using Log Rank and Breslow tests. Cox proportional hazards regression will
be used to calculate the univariate hazard ratio(HR) for the covariates significantly
associated with mortality and length of hospital stay.

14

Multivariable analysis:
In multiple linear regression model we will define the predictors of 24-hour urine
output by regressing the 24-hour urine output as a continuous outcome variable on 24
hours Furosemide dose including potential confounders in the model. We will include an
interaction term between CKD and Furosemide. Backward Elimination method will be
used to obtain the final model.
Cox proportional hazards regression analyses will be used to estimate Hazard
Ratio and 95% CI for Hazard Ratio of hospital discharge in aggressive vs. non-aggressive
diuretic therapy group. We will obtain variables for multivariable Cox proportional
model via entry of all univariate baseline predictors of discharge from hospital with a
value of P<0.2 and predictors first twenty-four hours urine output from multivariable
linear regression model mentioned earlier. Using backward selection and starting with a
variable with the largest P value, we retained variables that altered the HR by >10 % in
the final model. Proportional- hazards assumption will be tested by visual inspection of
log-minus-log survival plots and cumulative martingale residue plot. The main effects
and all covariates found to be in violation of the proportional- hazards assumption will be
appropriately transformed.
Statistical analysis will be performed with SPSS version 24.0 (SPSS Inc, Chicago,
IL) and SAS version 9.4 (SAS Inst., Cary, NC) Significance will be defined as the 2tailed value of P<0.05.

15
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RESULTS:
483 patients met screening criterion initially. We excluded 289 cases because of
age above 80 years of age, dialysis dependent End Stage Renal Disease (ESRD) and
other acute medical illness concurrently (See Figure1). 194 cases were included in the
analysis. 165 met criterion of non-aggressive diuresis and 29 met criterion for aggressive
diuresis. Follow up was complete in all cases. Six patients died in the non-aggressive
group because of unrelated causes and were censored in time to event analysis.
In the total cohort, total first maximum twenty-four hours urine output ranged
from 110ml to 5800mL with mean 1372 ±1009 mL. Total maximum twenty-four hours
Furosemide dose ranged from 40mg to 240mg with median dose 80 and IQ range of 4080. Total range of length of hospital stay was 1 to 28 days with a median of 5 days and
IQ range of 3-8 days.
Means of age (P=0.09), left ventricular ejection fraction (P=0.78) were
comparable between aggressive and non-aggressive diuresis group. First twenty-four
hours total dose of Furosemide used was significantly higher in aggressive diuresis
groups as compared to non-aggressive diuresis group (P=0.049). Similarly, mean systolic
blood pressure at admission (144 ± 23 versus 135±23; P=0.046) and mean 24-hour urine
output (3209 ±903 versus 1049± 598; P< 0.001) were significantly higher in aggressive
diuresis group than the non-aggressive group. Distributions of sex, race, and type of heart
failure were comparable between two groups (P>0.05). A smaller proportion of patients
developed kidney dysfunction in non- aggressive diuresis group as compared to
aggressive diuresis group, but it was not found to be statistically significant (6.9% versus
17

12.15%; P = 0.2). A smaller proportion of patients were found to have an episode of
hypotension in the aggressive diuresis group as compared to the non-aggressive diuresis
group, but it was not found to be statistically significant (6.9% versus 13.9 %; P=0.38).
There were six deaths noticed in total in non-aggressive diuresis group only. Eight
patients were noted to have an arrhythmia in the non-aggressive diuresis group as
compared to 1 in aggressive diuresis group.
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Table 2: Characteristics of Patients

Characteristics

Total Cohort

Non-aggressive
diuresis a

Aggressive
diuresis a

P value

Age(years)
Mean(SD)
Race
White

72(11)

72(10)

69(12)

0.09

182(93.8%)

153(92.7%)

29 (100%)

0.22

Non-white

12(6.2%)

12(7.3%)

0(0 %)

96(49.5%)
98(50.5%)

80 (48.5%)
85 (51.5%)

16 (55.2%)
13 (44.8%)

0.51

112(57.7%)
82(42.3%)

96(58.2%)
69(41.8%)

16(55.2%)
13(44.8%)

0.76

40(16)

40(16)

41(15)

0.78

137(23)

135(23)

144(23)

0.046*

1.33(0.57)

1.33(0.56)

1.31(0.63)

0.86

80(40-80)

70(40-80)

80(55-120)

0.049*

1372(1009)

1049(598)

3209(903)

<0.001*

22(11.3%)
172(88.7%)

20 (12.15%)
145(87.9%)

2(6.9%)
27(93.1%)

0.54

Sex
Male
Female
Type of Congestive
Heart Failure
Systolic
Diastolic
Left Ventricular
Ejection Fraction (%)
Mean(SD)
Systolic Blood pressure
on Admission (mmHg)
Mean(SD)
Creatinine at Time of
Admission mg/dL)
Mean(SD)
Dose of Furosemide
used(mg) †
Median(IQ)
24 Hour Urine
output(mL)
Mean(SD)
Worsening of Kidney
Function
Yes
No
Hypotension
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Yes
No
Death
Yes
No
Arrhythmia
Yes
No

25(12.9%)
169(87.1%)

23(13.9%)
142(86.1%)

2(6.9%)
27(93.1%)

0.38

6(3.1%)
188(96.9%)

6(3.6%)
159(96.4%)

0(0%)
29(100%)

0.59

9(4.6%)
185(95.4%)

8(4.8%)
157(95.2%)

1(3.4%)
28(96.6%)

1

P value refers to the difference between aggressive and non-aggressive diuresis groups.
*Significant
†Loop diuretic dose reported as median with interquartile range; all other values represent mean±SD or %.
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The final multivariable linear regression model after backward elimination
showed statistically significant main effect (P<0.001) of a dose of Furosemide in
increasing first twenty-four hours urine output along with its interaction with creatinine at
the time of admission, depicting higher dose of Furosemide required to produce the same
amount of urine with greater than 1.6mg/dL creatinine on admission. (P=0.02). See Fig 2,
Table 3.
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Table 3: Multiple Linear Regression model with 24 Hour Urine output regressed
on Dose of Furosemide, Creatinine at the time of Admission
Characteristics

Coefficient

Standard
Error

95% CI

t

P

intercept

556.88

190.91

180.31 to 933.45

2.91

0.004

Furosemide

12.14

2.43

7.35 to 16.94

5.00

Cr > 1.6

395.26

322.42

-240.73 to 1031.25

1.23

<0.001
*
0.22

Cr >1.6 X
Furosemide

-8.98

3.47

-15.83 to -2.14

-2.59

0.02*

Furosemide, Total 24 hours dose of Furosemide used in 24 hours; Cr>1.6, indicates greater than 1.6 mg/dL
serum creatinine at time of admission equivalent to stage 3 or less kidney disease; Cr>1.6 X Furosemide,
indicates interaction between furosemide and creatinine greater than 1.6mg/dL.*Significant
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Kaplan Meier estimate of the median accumulated proportion of patients still in
hospital in aggressively diuresed patients(n=29) was 4 days as compared to 5 days in
non-aggressively diuresed patients (n=165). Log–Rank test (P=0.67) and Breslow test
(0.77) revealed non-significant differences between the accumulated hospitalized
proportion over time.
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Table 4 Summary of Kaplan – Meir Estimate for Cohort- total Study Sample of 194
Patients

Time
(days)

Accumulated
Proportion
patient in
Hospital (%)

2

0.80

4

0.53

6

0.32

8

0.20

10

0.15

95% CI
(%)

Number of
patients
discharged

0.74 to
0.86
0.45 to
0.61
0.26 to
0.38
0.15 to
0.26
0.09 to
0.21

25

Number
patients
censored

Number
at Risk

38

0

156

91

2

101

131

0

61

153

1

38

163

1
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Table 5 Survival Characteristics of subgroup of Study Sample

Group

Aggressive diuresis
Non-aggressive
Diuresis

No of
total
Patients

Median
Total Number of
Total
Hospital stay in
Patients
Number
days
Discharged
Censored
95% (CI)

29

29

0

4 (2.95 to 5.06)

165

159

6

5 (4.40 to 5.60)

26

27

Table 6 Univariate Cox Proportional Hazards Regression Model Showing effect of
Aggressive Diuresis on Risk of Discharge from Hospital.

Characteristics Coefficient
Aggressive
diuresis

0.079

Standard
Error

Wald
χ2

P
value

Hazard
Ratio

95%
CI

0.20

0.15

0.70

1.08

0.73 to
1.61
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Table 7: Cox Proportional Hazards Regression Model Showing the Effect of Four
Variables on Risk of Discharge from Hospital

Characteristics Coefficient

Standard
Error

Wald
χ2

P
value

Hazard
Ratio

Aggressive
diuresis

0.11

0.21

0.27

0.60

1.12

LVEF

0.007

0.005

2.19

0.14

1.01

Furosemide

<0.001

0.003

0.001

0.98

1.000

Cr >1.6

-0.10

0.33

0.10

0.75

0.90

Cr >1.6 X
Furosemide

0.001

0.004

0.07

0.79

1.001

95%
CI
0.74 to
1.68
1.00 to
1.017
0.995 to
1.005
0.47 to
1.72
0.99 to
1.01

Aggressive diuresis, indicates greater than or equal 2400mL/ 24 Hour urine; LVEF, Left
Ventricular Ejection Fraction; Furosemide, Total 24 hours dose of furosemide used in 24 hours;
Cr>1.6, indicates greater than 1.6 mg/dL serum creatinine at time of admission equivalent to
stage 3 or less kidney disease; Cr>1.6 X Furosemide, indicates interaction between furosemide
and creatinine greater than 1.6mg/dL.
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In univariate analysis, Cox proportional hazards regression showed the unadjusted
hazard rate of discharge from hospital was similar to patients with aggressive diuresis, as
results did not approach statistical significance (HR=1.08; P=0.70). Similarly, in
multivariate Cox model creatinine at the time of admission when greater than 1.6mg/dL
(P=0.75), left ventricular ejection fraction (P= 0.14), total 24 hours dose of furosemide
given (P=0.98) and interaction between Furosemide and Creatinine (P=0.79) were not
statistically significant. The hazard rate of discharge from Hospital was 12% higher in
aggressive diuresis group then non-aggressive diuresis but still statistically nonsignificant (adjusted HR=1.12; P=0.6).
DISCUSSION:
A diuretic is a primary agent used in acute CHF. The effect of a diuretic on urine
output is modified by patient-related comorbidities and concurrent administration of other
medications. It is a common observation that the dose required for the same amount of
diuresis varies not only between patients with similar comorbidities but additionally
within the same patient during different hospitalizations. Loop diuretics over a period can
lead to diuretic resistance with persistent fluid overload. It is likely from the activation
renin-angiotensin-aldosterone system and sympathetic nervous system, hence reducing
renal blood flow, decreasing the filtered sodium and increasing its reabsorption. Chronic
loop diuretic therapy also leads to hypertrophy of epithelial cells in the distal tubules thus
increasing sodium absorption 9,10. Other factors responsible are decreased drug delivery
to nephron and hyperchloremia.11 These mechanisms make dose response unpredictable.
Despite this heterogeneity in responses, ROSE randomized controlled trial which
recruited patients with advanced heart failure showed the effect of diuresis of loop
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diuretic to be unchanged even if combined with other medications. In this RCT one of the
primary endpoints was the 72-hour cumulative urine volume as an index of diuresis.
After 72-hours study investigators did not find a difference in total median dose of
diuretic required as well as cumulative urine output in three combination groups (placebo
with furosemide, low-dose dopamine with furosemide, and low-dose nesiritide with
furosemide). 6,12 Extending the same concept to our study and ignoring the use of other
medication, as expected the group with higher diuresis (aggressive diuresis group) had a
higher median dose of diuretic than the non-aggressive group. We found a linear
relationship between the loop diuretic dose and first twenty-four hours urine output
modified by worse kidney dysfunction. As higher urine output would lead to early relief
of symptoms with congestion, we expected an earlier discharge of a patient with higher
first twenty-four hours urine output, however to our surprise, there was no statistically
significant difference between the hazards of discharge of the patients in two groups.
There appeared to be a disconnect, as high diuresis achieved in first twenty-four hours
did not translate into a shorter hospital stay. There can be many explanations. Length of
hospital stay might have been affected by the subsequent different daily dose of diuretic
depending on the clinical course. Patients in the non-aggressive diuretic therapy group
with lesser urine output might have had incomplete relief of congestion, and in turn had
to be given smaller doses for a longer period thus increasing the length of hospital stay.
On the other hand, the patients who were in the aggressive diuresis therapy group might
have had adverse effects as worsening of kidney function, hypotension or electrolyte
disturbances, notorious with a higher diuretic dose thus might have required subsequent
dose reduction leading to less urine ouptut.13-16 Number of adverse effect in each group
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are not reliable in our study as these were counted in the first twenty-four hours only and
study was not powered to detect the adverse outcome difference. It appears that the
advantage of increased urine output in the first twenty-four hours was offset by the low
urine output in subsequent days, leading to comparable total days of hospital stay.
Secondary analysis of ESCAPE trial showed that when aggressive diuretic
therapy was used, excess reduction in the intravascular volume measured by surrogate
markers of hemoconcentration and protein concentration directly correlated with
worsening of kidney function. After aggressive diuresis with higher dose there a was a
greater change in weight (fluid loss) leading to decrease in pulmonary wedge pressure
and right atrial pressure, as well as poor perfusion to kidneys and worsening kidney
function likely explaining cardiorenal syndrome.17 Similarly, a higher dose of loop
diuretic theoretically leads to hemodynamic disturbance causing hypotensive episodes
due to reduced cardiac index and reduction in filling. DOSE trial used a 2-by-2 factorial
design to test Furosemide in low vs. high dose as a continuous IV vs. bolus IV dose to
find a difference in primary endpoints of improvement in patient symptoms and
worsening of renal function in any specific group.7 The study found no difference in
primary endpoints as well as a one of its prespecified secondary endpoint; the length of
hospital stay. Since our study has shown a linear relationship between urine output and
the dose of Furosemide modified by baseline creatinine, we can safely argue that there
was higher urine output in high dose arm of Furosemide DOSE trial as there was no
difference in baseline creatinine in any group. Despite higher urine output, it did not
result in a shorter hospital stay. It corresponds with our finding that amount of diuresis
predicts the degree of decongestion and relief of symptoms better than the surrogates; the
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amount of loop diuretic used directly. The amount of urine output still does not influence
the length of hospital stay. Howard and Dunn conducted a non-randomized prospective
study on >65-year old patient with NYHA class IV CHF. Treatment arm involved
aggressive diuretic therapy in achieving the goal of ≥ 2400/24hours urine output. This
lead to a shorter hospital stay of 2.3 days and lesser cost than the non-aggressive
(standard medical care group). Results in that study are appealing but likely biased due to
the use of particular subset population in the treatment group, a small sample of 17 only,
non-randomized design and differential close monitoring of the intervention group for the
signs of decongestion, adverse effects as well as prompt replacement of electrolytes
especially chloride to avoid resistance. 3 Li and Hong in China conducted a similar
retrospective cohort study design on 195 patients. After implementing same cutoffs to
define the aggressive diuretic therapy as urine output of ≥ 2400mL/24 hour, they found a
shorter length of hospital stay(aggressive diuretics therapy: 11 days vs. non-aggressive
therapy: 16 days; P< 0.05 ).8 Although the study has a similar design as our study results
are different possibly because the average length of hospital stay in their groups was 13.5
days much higher than our mean duration of 5 days for our total study cohort. It is likely
related to the intrinsic difference in population or treatment difference in two countries.
In ESCAPE Trial, aggressive diuresis using the pulmonary wedge pressure based
monitoring method vs standard clinical assessment method did not show significant
difference in endpoint of total 6 months mortality after randomization as well as
difference in prespecified endpoint of mean number of days hospital stay (aggressive
diuretics therapy: 8.7 days vs non aggressive therapy : 8.3 days; P= 0.67 ). There was no
comparison of the urine output in the groups, but we can argue that pulmonary wedge
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pressure directed group had higher urine output, but still there was no difference in length
of hospital stay17,18.
LIMITATIONS:
Our study has inherent limitations of any retrospective study. Since it not
prospective blinded RCT study and all patient were a subset of all acute CHF patient
from a single center meeting inclusion criterion, results of this study might have some
selection bias and all unknown confounders might not have been controlled. Patients
were included with first-time hospital admission or on readmission with a primary
diagnosis of acute CHF, but other coexistent comorbidities potentially complicating the
hospital course were not included. We did not have data on weight, dietary sodium and
fluid intake, or BNP levels in patients at the time of admission. Since diuretic dose and
urine output was limited to first twenty-four hours and not during complete hospital
course, it limits the ability to determine the temporal relationship between urine output
and length of hospital stay. The proportion of patient in each group were not equal as
expected during the assessment of the power of study, thus it will affect the actual total
power study was able to achieve.

CONCLUSION:
To date, clinicians have no clear evidence-based strategies for safely and rapidly
improving congestion in patients with acute CHF. Our study showed higher diuretic dose
based on the inherent desire to increase diuresis for a quicker relief of symptoms is
associated with higher urine output and possibly untoward adverse effects during the
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hospital course. Thus patients with higher and low urine output tend to stay a comparable
total number of days in the hospital. Although these results are in line with the possible
pathological mechanism, there were methodological limitations with small sample size.
As a result, we suggest challenging rather than changing current conceptions about
monitoring the diuresis in a patient with dose of loop diuretic rather than the amount of
urine output. Future research necessary in large prospective randomized controlled trials
to assess the direct effect of amount diuresis rather than the dose of diuretics in the relief
of signs or symptoms or radiological improvement in congestion, readmission, mortality,
biochemical parameters and cost of hospital admission. We suggest an adequate dose of
diuretic to keeping the goal of daily diuresis less than 2400mL/24 hours.

35

REFERENCES:
1.

Writing Group M, Benjamin EJ, Blaha MJ, et al. Heart Disease and Stroke
Statistics—2017 Update: A Report From the American Heart Association.
Circulation. 2017;135(10):e146-e603.

2.

McHugh MD, Ma C. Hospital Nursing and 30-Day Readmissions among
Medicare Patients with Heart Failure, Acute Myocardial Infarction, and
Pneumonia. Medical care. 2013;51(1):52-59.

3.

Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly.
Chest. 2001;119(3):807-810.

4.

Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P. Economic burden of
hospitalizations of Medicare beneficiaries with heart failure. Risk Management
and Healthcare Policy. 2017;10:63-70.

5.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update
of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A
Report of the American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines and the Heart Failure Society of America.
Circulation. 2017.

6.

Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose
nesiritide in acute heart failure with renal dysfunction: The rose acute heart failure
randomized trial. JAMA. 2013;310(23):2533-2543.

7.

Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute
decompensated heart failure. N Engl J Med. 2011;364(9):797-805.

36

8.

Li JB, Hong HS. [The value of aggressive diuretic therapy in acute
decompensated stage of chronic heart failure]. Zhongguo Wei Zhong Bing Ji Jiu
Yi Xue. 2011;23(6):359-362.

9.

Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of
diuretic responsiveness with prognostic importance in acute decompensated heart
failure. Circ Heart Fail. 2014;7(2):261-270.

10.

Gerlag PG, van Meijel JJ. High-dose furosemide in the treatment of refractory
congestive heart failure. Archives of internal medicine. 1988;148(2):286-291.

11.

Brater DC. Resistance to loop diuretics. Why it happens and what to do about it.
Drugs. 1985;30(5):427-443.

12.

Ahmad T, Jackson K, Rao VS, et al. Worsening Renal Function in Acute Heart
Failure Patients Undergoing Aggressive Diuresis is Not Associated with Tubular
Injury. Circulation. 2018.

13.

Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of
arrhythmic death in patients with left ventricular dysfunction. Circulation.
1999;100(12):1311-1315.

14.

Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated
with increased short-term mortality in hospitalized patients with worsening heart
failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone
for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation.
2005;111(19):2454-2460.

37

15.

Hasselblad V, Stough WG, Shah MR, et al. Relation Between Dose of Loop
Diuretics and Outcomes in a Heart Failure Population: Results of the ESCAPE
Trial. European journal of heart failure. 2007;9(10):1064-1069.

16.

Wright SP, Verouhis D, Gamble G, Swedberg K, Sharpe N, Doughty RN. Factors
influencing the length of hospital stay of patients with heart failure. Eur J Heart
Fail. 2003;5(2):201-209.

17.

Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of
aggressive decongestion during the treatment of decompensated heart failure on
renal function and survival. Circulation. 2010;122(3):265-272.

18.

The EI, Coordinators* ES. Evaluation study of congestive heart failure and
pulmonary artery catheterization effectiveness: The escape trial. JAMA.
2005;294(13):1625-1633.

38

Vita:
Muhammad Umer Butt M.D. is a National Heart Lung Blood Institute (NHLBI)
sponsored Ruth L. Kirschstein National Research Service Award (NRSA) T32 Postdoctoral
Fellow in Cardiology at University of Kentucky. He is also a candidate of Master of Science in
Clinical Research Design (MSCRD) and Certificate in Biostatistics at University of Kentucky. He
received his M.D. from King Edward Medical University Lahore, Pakistan. He completed his
Internal Medicine Residency at the State University of New York at Buffalo Affiliated Hospitals.
He will be moving to Cleveland, Ohio for his Clinical Cardiology fellowship and later Cardiac
Electrophysiology fellowships at Case Western University Affiliated Hospitals. On completion,
he aspires to pursue his career as an academic physician-scientist.

39

